Nathan Standifer

4PUBLICATIONS
74CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Mar 29, 2024
First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.

Mark Yarchoan, John D Powderly, Bruno R Bastos

|Feb 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar

|Feb 24, 2023
Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma.

Julio C Chavez, Francine M Foss, Basem M William

|Dec 08, 2022
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.

Xuyang Song, Robin Kate Kelley, Anis A Khan

Pageof 1

Frequent Collaborators

1 joint publications

Xuyang Song

1 joint publications

Robin Kate Kelley

1 joint publications

Anis A Khan

1 joint publications

Diansong Zhou